Exscientia Market Research Report
Company Overview
Name
Exscientia
Mission of the Company
Pairing the best human science and tech expertise with the capacity of AI, machine learning, and automation to discover high-quality drugs faster is what drives Exscientia. By applying AI to precision engineer medicine candidates more rapidly and efficiently, Exscientia enables people to live healthier and more productive lives.
Founded and By Whom
No information is available.
Key People in the Company
- David Hallett: Chief Executive Officer (interim) & Chief Scientific Officer, Executive Director
- Ben Taylor: CFO & Chief Strategy Officer, Executive Director
- Marie-Louise Fjällskog: Chief Medical Officer (interim) & Clinical Development Lead
- Dan Ireland: EVP, Legal, Company Secretary
- Nikolaus Krall: EVP, Precision Medicine
- Richard Law: Chief Business Officer
- Parker Moss: EVP, Corporate Development
- John Overington: Chief Technology Officer
- Caroline Rowland: Chief People Officer
Board of Directors
- Elizabeth Crain: Chair of the Board, Moelis & Company
- David Hallett
- Ben Taylor
- Franziska Michor: Dana-Farber Cancer Institute
- Mario Polywka: Evotec Supervisory Board
- Robert Ghenchev: Novo Holdings
Headquarters
The Schrödinger Building, Oxford Science Park, Oxford, OX4 4GE, United Kingdom
Number of Employees
No information is available.
Revenue of the Company
No information is available.
What Is the Company Known For?
Exscientia is known for being the world’s leading technology-driven drug design and development company. They are recognized for their patient-first AI platform, spearheading the drug discovery revolution with the first AI-designed molecules to reach clinical trials.
Products
Overview
Exscientia offers AI platforms and a pipeline of precision-engineered, patient-centric therapeutic candidates.
Key Products and Features
EXSCIENTIA AI PLATFORM
- Efficient: Tests roughly 1/10th of the compounds conventionally required.
- Quality: Designs against key criteria from the outset for successful drug properties.
- Speed: From project start to candidate molecule in less than one year.
Pipeline Programs
- GTAEXS617 (CDK7, Advanced Solid Tumours): Wholly Owned, Late Discovery
- EXS4318 (PKC-theta, Inflammatory Diseases): Milestones & Royalties, Phase 1 Healthy Volunteer
- EXS74539 (LSD1, AML, SCLC): Wholly Owned, Late Discovery
- EXS73565 (MALT1, Haematology): Wholly Owned, Late Discovery
Recent Developments
Recent Developments in the Company
- Exscientia’s AI-designed molecules have reached clinical trials.
- They have demonstrated improved treatment outcomes in a prospective interventional study through their patient-first AI platform.
- Exscientia is integrating generative AI drug design and robotic lab automated make-and-test molecules.
New Products Launched
No information is available.
New Features Added to Existing Products
No information is available.
New Partnerships
No information is available.
This report is based on the data available from Exscientia. Missing information is explicitly marked as "No information is available".
